Display Settings:

Format

Send to:

Choose Destination
Pol Arch Med Wewn. 2009 Oct;119(10):648-53.

Do alpha-reductase inhibitors prevent prostate cancer? 2008 practice guideline from the American society of clinical oncology and American urological association.

Author information

  • 1Department of Urology, RWTH University of Aachen, Aachen, Germany.

Abstract

As new guidelines on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention produced by the American Society of Clinical Oncology (ASCO) and American Urological Association (AUA) have recently been published, the use of 5-ARIs is becoming of increasing interest. We analyzed the current evidence to support the use of 5-ARIs in the prevention of prostate cancer. We therefore compared the new guidelines of the ASCO and AUA with the current data concerning the use of 5-ARIs in the prevention of prostate cancer. At present, there is still an open debate going on whether or not it is advisable to incorporate the use of 5-ARIs as chemopreventive agents in daily practice.

PMID:
19847141
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medycyna Praktyczna
    Loading ...
    Write to the Help Desk